AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02548468
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01411072
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gem 1000 mg/m2 IV weekly for 3 weeks then one week off of each 28 day cycle
Trial: NCT01411072
Drug: 5-fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU 425 mg/m2 and Leucovorin 20 mg/m2 IV day 1, 2, 3, 4, and 5 of each 28 day cycle
Trial: NCT04304950
Drug: Evening Group
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will take their IBD medication (either azathioprine or 6-mercaptopurine) between 6:00 pm and 11:00 pm.
Trial: NCT03178422
Drug: CQSS2
RxNorm normalized name: Chloroquine Sulfate
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine Replacement Therapy
Trial: NCT02629965
Drug: tiotropium
RxNorm normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fixed dose combination
Trial: NCT02629965
Drug: olodaterol
RxNorm normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: fixed dose combination
Trial: NCT02629965
Drug: tiotropium
RxNorm normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02826603
Drug: Secukinumab
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300mg, s.c. at randomization, Weeks 1, 2 and 3 and thereafter 4-weekly till Week 48
Trial: NCT02826603
Drug: Ustekinumab
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Per approved label, 45 mg or 90 mg s.c. based on subject weight (at randomization visit) to be administered at randomization, Week 4, 16, 28 and 40. At other timepoints subjects will receive placebo injections.
Trial: NCT00636428
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral midazolam, was prepared into a final solution (2.5 mg/mL) from injectable midazolam hydrochloride and a orange flavored syrup. For preparation, midazolam injection (5 mg/mL) was diluted 1:1 with the flavored syrup.
Trial: NCT01337050
Drug: PF-03446962
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF 03446962 given by a 1 hour IV infusion. Each patient will initially receive the first dose on Cycle 1 Day 1 with a 28 day observation period. Cycle 2 will start on Day 29. The dosing interval will be 14 days for Cycle 2 and subsequent cycles.
Trial: NCT04736979
Drug: amoxicillin clavulanate
RxNorm normalized name: amoxicillin / clavulanate
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dosage according to Shariff score and creatinine clearance
Trial: NCT02061085
Drug: Eribulina
RxNorm normalized name: Eribulina
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02667873
Drug: SL-801
RxNorm normalized name: pirfenidone 801 MG
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: SL-801 is a small-molecule inhibitor of the nuclear export protein Exportin-1 (XPO1).
Trial: NCT02914015
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * 0.6ml/kg 0.5% ropivacaine with 1:200,000 adrenaline given immediately after the correct position of the tip of the needle has been verified.~* followed with 0.2% ropivacaine infusion at a rate of 0.125ml/kg/h given through the catheter inserted in between the quadratus lumborum muscle and psoas major muscle.
Trial: NCT02914015
Drug: Morphine given as IPCA
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bolus: 1-2mg, lock time: 10min, 1h limitation: 5-10mg. without background infusion.
Trial: NCT04136171
Drug: Eplontersen
RxNorm normalized name: EPLONTERSEN
DrugBank: Eplontersen (DB16199)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplontersen by subcutaneous injection
Trial: NCT02903069
Drug: TMZ
RxNorm normalized name: TMZ
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TMZ will be administered once daily, 7 days/week, for 6 weeks, starting on Day 1, at a dose of 75 mg/m2 during Concomitant Treatment.~TMZ will be administered once daily on Days 1-5 every cycle, dose range 150 to 200 mg/m2 during Adjuvant Treatment.
Trial: NCT03298672
Drug: NDX-1017
RxNorm normalized name: NDX-3315
DrugBank: NDX-3315 (DB18671)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution of NDX-1017 for subcutaneous injection
Trial: NCT01306461
Drug: Timolol and Tafluprost
RxNorm normalized name: Tafluprost
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Preservative-free Timolol eye drops administered twice daily concomitantly with preservative-free Tafluprost eye drops administered once daily~Treatment period 6 months
Trial: NCT02017171
Drug: Allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01306461
Drug: Fixed Dose Combination of tafluprost and timolol
RxNorm normalized name: Tafluprost
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Preservative-free Fixed Dose Combination of tafluprost and timolol eye drops administered once daily.~For masking purposes also: vehicle for timolol administered twice daily~Treatment period 6 months
Trial: NCT03558997
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dupilumab was administered SC in a single-use, pre-filled glass syringe
Trial: NCT03558997
Drug: Timothy Grass SCIT
RxNorm normalized name: Timothy grass
DrugBank: Phleum pratense top (DB14179)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timothy grass extract was administered SC.
Trial: NCT03558997
Drug: Placebo matching dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Placebo matching dupilumab was prepared in the same formulation without the addition of protein
Trial: NCT02255578
Drug: clomiphene citrate treatment
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00097851
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00097851
Drug: PI-88
RxNorm normalized name: Heparanase inhibitor PI-88
DrugBank: Muparfostat (DB05808)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03800290
Drug: Clenbuterol Hydrochloride
RxNorm normalized name: Clenbuterol Hydrochloride
DrugBank: Clenbuterol (DB01407)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily ingestion of clenbuterol hydrochloride capsules (40 microgram/day) for a total period of 14 days with a wash-out period of 4 weeks.
Trial: NCT01387165
Drug: Treatment
RxNorm normalized name: Acne Treatment
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: were receiving an oral hypoglycemic agent (OHA) or insulin
Trial: NCT03882710
Drug: Metoprolol XR
RxNorm normalized name: metoprolol Extended Release Oral Capsule
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol XR capsule 25/50/100 mg once daily for 12 weeks
Trial: NCT04485273
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane in air/oxygen mixture of 40% is titrated to achieve adequate depth of anesthesia.
Trial: NCT01164384
Drug: Baminercept
RxNorm normalized name: Baminercept
DrugBank: Baminercept (DB06576)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01304784
Drug: Cisplatin, Capecitabine, Trastuzumab and MM-111
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Conventional chemotherapy
Trial: NCT01304784
Drug: Lapatinib +/- Trastuzumab and MM-111
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Conventional chemotherapy
Trial: NCT01304784
Drug: Paclitaxel, Trastuzumab and MM-111
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Conventional chemotherapy
Trial: NCT01304784
Drug: Lapatinib, trastuzumab, paclitaxel, and MM-111
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Conventional chemo
Trial: NCT01304784
Drug: Docetaxel, trastuzumab and MM-111
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Conventional chemotherapy
Trial: NCT02056405
Drug: Mosapride
RxNorm normalized name: mosapride
DrugBank: Mosapride (DB11675)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg per day divided into 3 oral intakes of 5 mg each (1 pill of Mosapride every 8 hs with 30 ml tap water). This treatment will begin on postoperative day 1 until discharge from Hospital or unacceptable toxicity develops.
Trial: NCT00329940
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00079014
Drug: triapine
RxNorm normalized name: Triapine
DrugBank: Triapine (DB11940)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00125684
Drug: morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03783702
Drug: OxyCODONE 5 Mg (milligram) Oral Tablet
RxNorm normalized name: oxycodone 5 MG
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone will be the second-line treatment in the control group and the third-line treatment in the experimental group.
Trial: NCT03986762
Drug: Clavulanic Acid
RxNorm normalized name: Clavulanic acid
DrugBank: Clavulanic acid (DB00766)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: \~10 days of Clavulanic Acid
Trial: NCT02198339
Drug: BIBN 4096 BS
RxNorm normalized name: BS-001
DrugBank: BS-001 (DB17415)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01488266
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: patients who are randomly assigned to adjunctive aripiprazole are treated with a starting dose of 2.5 (or 5) mg/day of aripiprazole, which can be increased weekly in 2.5\~5mg/day increments to a maximum dose of 15 mg/day based on assessment of tolerability and clinical response. Doses can be decreased at any visit, based on tolerability; They continue to receive the same fixed-dose of the previously used antidepressant throughout the study period when patient is assigned to aripiprazole augmentation group.
Trial: NCT01488266
Drug: switching to different class of antidepressant
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients randomly assigned to switching to different antidepressant have to discontinue the previously used antidepressant and receive different antidepressant within flexible therapeutic doses as indication label information (as based on clinicians' preference and experience). Dose increase is permitted until the first 2 weeks of the study.
Trial: NCT01171170
Drug: carboplatin paclitaxel bevacizumab
RxNorm normalized name: Carboplatin
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: paclitaxel 200 mg/m2 d1 - carboplatin AUC 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression
Trial: NCT01171170
Drug: Standard treatment plus nitroglycerin
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: paclitaxel 200 mg/m2 d1 - carboplatin AUC 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression. Plus nitroglycerin transdermal patches 25 mg per day from day -3 till +2 of First combination cycle till the last bevacizumab monotherapy cycle
Trial: NCT02328261
Drug: Icotinib
RxNorm normalized name: icotinib
DrugBank: Icotinib (DB11737)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icotinib (125 mg tablet) is orally administered three times daily until disease progression or unaccepted toxicity.
Trial: NCT00931385
Drug: BI 1744
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI1744 Respimat Med Dose Once Daily
Trial: NCT00931385
Drug: Foradil
RxNorm normalized name: Foradil
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Foradil 12 mcg twice daily and Placebo Respimat
Trial: NCT02555059
Drug: Cipro (Ciprofloxacin, BAYQ3939)
RxNorm normalized name: ciprofloxacin Injection [Cipro]
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment parameters following the physician's decision based on the summary of product characteristics.
Trial: NCT02296125
Drug: Placebo Erlotinib 150/100mg
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The initial dose of Placebo Erlotinib 150 mg once daily can be reduced to Placebo 100 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Trial: NCT02296125
Drug: Placebo Gefitinib 250 mg
RxNorm normalized name: gefitinib 250 MG
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The initial dose of Placebo Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Trial: NCT02296125
Drug: Erlotinib 150/100 mg
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The initial dose of Erlotinib 150mg once daily can be reduced to 10 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label AZD9291 (crossover to active AZD9291).
Trial: NCT02296125
Drug: Gefitinib 250 mg
RxNorm normalized name: gefitinib 250 MG
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The initial dose of Gefitinib 250mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label AZD9291 (crossover to active AZD9291).
Trial: NCT04171141
Drug: PF-07062119
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-07062119
Trial: NCT04171141
Drug: Anti-PD1
RxNorm normalized name: Anti-pd1/ctla4 bispecific antibody xmab20717
DrugBank: Vudalimab (DB18833)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD1 PF-06801591
Trial: NCT04171141
Drug: Anti-VEGF
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-VEGF IV (bevacizumab)
Trial: NCT01140984
Drug: Methylprednisolone (Intra-arterial continuous infusion of corticosteroids)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sedation/anesthesia of patient followed by placement of a 4F vascular sheath and a diagnostic and hepatic angiogram. Angiographic catheter tip to be placed in the proximal proper hepatic artery, secured in place externally and connected to an arterial line pressurized system which allows continuous drip infusion of methylprednisolone diluted in normal saline (600mg/m2 with maximal total dose of 100mg diluted in 480cc in normal saline administered at 20cc/hr for 24 hours).
Trial: NCT01873079
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00185211
Drug: Interferon beta-1b (Betaseron, BAY86-5046)
RxNorm normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initial Betaferon/Betaseron treatment (Interferon beta-1b, IFNB-1b), 250 ug administered s.c. (subcutaneous) every other day, continued in Follow-up phase
Trial: NCT00185211
Drug: Interferon beta-1b (Betaseron, BAY86-5046)
RxNorm normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initial placebo treatment; Betaferon/Betaseron, 250 ug administered s.c. (subcutaneous) every other day offered in Follow-up phase (= this trial)
Trial: NCT01305317
Drug: Lipitor
RxNorm normalized name: Lipitor
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20mg daily for 6 months
Trial: NCT04304157
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine (DEX) a potent α 2 agonist that have unique analgesic, anxiolytic and sedative profile has been called upon as attractive adjunct in general as well as regional anesthesia with enticing results. Several studies have pursued DEX median effective dose (ED50) in different settings e.g., co induction agent with Propofol, in laryngeal muscle insertion and with local anesthetic to enhance the quality of spinal anesthesia
Trial: NCT00265798
Drug: Sorafenib Tosylate
RxNorm normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03122301
Drug: Stellate Ganglion Block injection with bupivicaine
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A computer-generated 1:1 block randomization scheme will be used to assign participants to receive either a SGB with bupivacaine or a sham injection with saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
Trial: NCT03122301
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sham injection with saline
Trial: NCT00973037
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen 20mg qd
Trial: NCT03526887
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg, Q3W
Trial: NCT04215146
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 80 mg/m\^2 1-hour IV infusion on days 1, 8, and 15 of a 28-day cycle.
Trial: NCT04215146
Drug: Avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab 10 mg/kg (not more than 800 mg) 1-hour IV infusion days 3 and 17 of a 28-day cycle.
Trial: NCT00066807
Drug: exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exemestane 25 mg orally daily for until 5 years from date of randomization, unless relapse or intolerance should occur earlier.
Trial: NCT00066807
Drug: tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen 20 mg orally daily until 5 years from date of randomization, unless relapse or intolerance should occur earlier.
Trial: NCT00066807
Drug: triptorelin
RxNorm normalized name: triptorelin
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triptorelin (GnRH analogue) 3.75 mg by intramuscular injection every 28 days for 5 years from randomization, unless relapse or intolerance should occur earlier or surgical oophorectomy or ovarian irradiation is subsequently performed.
Trial: NCT01172275
Drug: N-Acetylcysteine
RxNorm normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial.
Trial: NCT04206813
Drug: Gardasil 9 2 dose regimen
RxNorm normalized name: Gardasil 9
DrugBank: Human papillomavirus type 6 L1 capsid protein antigen (DB10299)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a 2-dose regimen of Gardasil 9 at 0 and 6 months
Trial: NCT04206813
Drug: Gardasil 9 3 dose regimen
RxNorm normalized name: Gardasil 9
DrugBank: Human papillomavirus type 6 L1 capsid protein antigen (DB10299)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard 3-dose regimen of Gardasil 9 at 0, 2, 6 months
Trial: NCT04206813
Drug: Gardasil 9 rescue dose
RxNorm normalized name: Gardasil 9
DrugBank: Human papillomavirus type 6 L1 capsid protein antigen (DB10299)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A rescue dose of Gardasil 9 will be given at 12 months
Trial: NCT01943409
Drug: Intralipid
RxNorm normalized name: Intralipid
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: soybean oil-based lipid emulsion
Trial: NCT01943409
Drug: ClinOleic
RxNorm normalized name: linoleate
DrugBank: Cholesteryl Linoleate (DB02092)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olive oil-based lipid emulsion